Tarık KARGIOĞLU, Gonca ALTINIŞIK İNAN, Hüseyin Furkan ÖZTÜRK, Feyza YAŞAR DAŞGIN

SBRT in the treatment of prostate cancer nodal relapse: A single-center experience and a brief literature review

Nodal recurrence after primary treatment of prostate cancer is increasingly encountered in the clinic. Although there is no specific recommended technique and dose schedule for radiotherapy applications, stereotactic body radiotherapy (SBRT) applications have been reported in most studies. This study aimed to retrospectively report the cases that underwent SBRT for prostate cancer nodal recurrence. Patients diagnosed with prostate cancer due to isolated nodal recurrence and undergoing SBRT were evaluated retrospectively. The patients' radiotherapy doses and target volume details were obtained from the technical file and planning system patient files and patient interviews. The primary endpoint of the study was a disease-free survey (DFS). Data were recorded and analyzed using SPSS ver. 24. The time from relapsed nodal SBRT to recurrence in or out of the SBRT area was defined as DFS after nodal RT. Kaplan Meier test was used for survival analysis. In the current study, a total of 10 field irradiation of 8 patients with prostate cancer who underwent RT for nodal recurrence between 16.8.18-18.2.21 in Ankara City Hospital were evaluated retrospectively. In the follow-up after diagnosis, isolated nodal recurrence developed in all the patients. The median DFSprimer was 6.9 (range 1.1-31.3) months. Median follow-up time after RT for nodal recurrence mean follow-up is 7 months (range 1-31.3). The median DFSafternodalRT was 3.5 months (range 1-26 months). During the follow-up period, intra-field recurrence was observed in one patient and extra-field recurrence was observed in two patients, and a total of 3 recurrences were observed. According to the results of the analysis, N stage at the time of diagnosis with DFSafternodalRT (p0.24); T stage at diagnosis (p0.47); diagnosis GS (p0.28); risk group at the time of diagnosis (p0.53); initial therapy (p0.67); baseline RT area (p0.057), presence or absence of surgery (p0.35); type of surgery (p0.64); PSA at diagnosis (p0.56); the relationship between the first RT dose (p0.053) were not statistically significant. The median duration of local-DFSafternodalRT is 3.7 months (Range 1-30 months). During the follow-up period, only one patient in the irradiated area had a recurrence. This case was unresponsive after RT and progression were observed. Nodal recurrence after RT Local-DFSafternodalRT diagnosis N stage (p0.28); T stage at diagnosis (p.36); diagnosis GS (p0.24); PSA at diagnosis (p0.52); risk group at the time of diagnosis (p0.57); initial therapy (p0.71); presence or absence of surgery (p0.38); type of surgery (p0.68); The relationship between the first RT total dose (p0.056), first RT areas (p0.054) were not statically significant. The only patient who did not respond and had local recurrence was the case who progressed after treatment, the primary RT area was quite large, and LV and PLN irradiation of the prostate lodge was performed. SBRT is a treatment choice for nodal recurrent prostate cancer; however, optimal dose scheme and timing are not determined.

PDF

___

1. Steuber T, Jilg C, Tennstedt P, et al. Standard of care versus metastasesdirected therapy for pet-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. 2019;5:1007-13.
2. Liskamp CP, Donswijk ML, van der Poel HG, et al. Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer. Clin Transl Radiat Oncol. 2020 26;22:9-14.
3. De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76:732-9.
4. Ponti E, Lancia A, Ost P, et al. Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 2017;3:538-44.
5. Bernard B, Gershman B, Karnes RJ, et al. Approach to oligometastatic prostate cancer. Am Soc Clin Oncol Educ Book. 2016;35:119-29.
6. Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983-8.
7. Schmidt-Hegemann NS, Buchner A, Eze C, et al. PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis. Strahlenther Onkol. 2020;196:637-46.
8. Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol). 2010;22:157-72.
9. Mahase SS, D’Angelo D, Kang J, et al. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the united states. JAMA Netw Open. 2020;3:e1920471.
10. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTROESUR-SIOG guidelines on prostate cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263-82.
11. Khondakar NR, Owens-Walton J, Daneshvar M, et al. Emerging role for local therapy in oligometastatic prostate cancer. Clin Adv Hematol Oncol. 2021;19:460-7.
12. Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15-25.
13. Kamran SC, D'Amico AV. Radiation therapy for prostate cancer. Hematol Oncol Clin North Am. 2020;34:45-69.
14. Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299-309.
15. Bravi CA, Fossati N, Gandaglia G, et al. Assessing the best surgical template at salvage pelvic lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: when can bilateral dissection be omitted? results from a multi-institutional series. Eur Urol. 2020;78:779-82.
16. Claeys T, Van Praet C, Lumen N, et al. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome. Biomed Res Int. 2015;2015:198543.
17. Tilki D, Mandel P, Seeliger F, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol. 2015;193:484-90.
18. Panje C, Zilli T, Dal Pra A, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019 16;14:177.
19. Viani GA, Arruda CV, Hamamura AC, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence: A meta-analysis. Am J Clin Oncol. 2020;43:73-81.
20. Vilela RA, Navarro NF, Faria ET, et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review. J Med Imaging Radiat Oncol. 2018;62:692-706.
21. Carrasquilla M, Creswell ML, Pepin AN, et al. Rationale for involved field stereotactic body radiation therapy-enhanced intermittent androgen deprivation therapy in hormone-sensitive nodal oligo-recurrent prostate cancer following prostate stereotactic body radiation therapy. Front Oncol. 2021 18;10:606260.
22. Tran S, Jorcano S, Falco T, et al. Oligorecurrent nodal prostate cancer: longterm results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41:960-2.
23. De Bruycker A, Spiessens A, Dirix P, et al. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020 12;20:406.
24. Oehler C, Zimmermann M, Adam L, et al. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. BMC Urol. 2019 9;19:84.
25. Ponti E, Ingrosso G, Carosi A, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13:e279-e284.
26. Loi M, Di Cataldo V, Francolini G, et al. Single-fraction stereotactic body radiotherapy for oligometastatic lymph node relapse in prostate cancer. Oncol Res Treat. 2018;41:703-5.
27. Ingrosso G, Trippa F, Maranzano E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35:45-9.
28. Detti B, Bonomo P, Masi L, et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World J Urol. 2015;33:1197-203.